Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPV-058 extension study of long-term immune persistence in healthy Chinese females
2017-000255-50Phase 3
- Sponsor
- GSK
- Start
- Mar 2018
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Walrinvax in human papillomavirus infection, sponsored by GSK. Primary endpoint: Anti-HPV-16/18 seropositivity rates and antibody concentrations at Visit 1.
02
Drugs
Walrinvax
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on 2017-000255-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000255-50.